Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Employment agrmnt Quarterly results Director departure Appointed director Notes underwriting agrmnt
|
SANUWAVE Health, Inc. (SNWV)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/12/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
10/10/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
10/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
09/29/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
08/24/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
08/23/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
08/23/2023 |
8-K
| Acquisition/merger/asset purchase announced
Docs:
|
"Agreement and Plan of Merger, by and among SEP Acquisition Corp., SEP Acquisition Holdings Inc., and SANUWAVE Health, Inc",
"Form of Voting Agreement, by and among SEP Acquisition Corp., SANUWAVE Health, Inc., and the stockholder of SANUWAVE Health, Inc. party thereto",
"Sponsor Voting Agreement, by and among Mercury Sponsor Group I LLC, SEP Acquisition Corp., and SANUWAVE Health, Inc",
"Form of Lock-Up Agreement, by and between SEP Acquisition Corp. and the stockholder of SANUWAVE Health, Inc. party thereto",
"Exhibit 99.1" |
|
08/22/2023 |
SC 13D/A
| MANCHESTER MANAGEMENT CO LLC reports a 11.7% stake in Sanuwave Health, Inc. |
08/11/2023 |
8-K
| Quarterly results |
08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/09/2023 |
4
| MANCHESTER MANAGEMENT CO LLC (Director by Deputization) has filed a Form 4 on SANUWAVE Health, Inc.
Txns:
| Converted 71,875,000 shares
@ $0.04, valued at
$2.9M
Converted 10,442,806 shares
@ $0.04, valued at
$417.7k
Converted options to buy
@ $0.04, valued at
$0 Converted options to buy
@ $0.04, valued at
$0 |
|
08/08/2023 |
3
| Walko Andrew (President) has filed a Form 3 on SANUWAVE Health, Inc. |
08/07/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
07/31/2023 |
8-K
| Quarterly results |
07/27/2023 |
SC 13D/A
| MANCHESTER MANAGEMENT CO LLC reports a 13.1% stake in Sanuwave Health, Inc. |
07/27/2023 |
4
| MANCHESTER MANAGEMENT CO LLC (Director by Deputization) has filed a Form 4 on SANUWAVE Health, Inc.
Txns:
| Acquired options to buy
@ $0 Acquired 12,500,000 warrants
@ $0 Acquired 1,875,000 warrants
@ $0 |
|
07/26/2023 |
8-K
| Quarterly results |
07/19/2023 |
8-K
| Quarterly results |
06/30/2023 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
06/29/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
05/16/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
05/12/2023 |
8-K
| Quarterly results |
05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
04/03/2023 |
8-K
| Quarterly results |
03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/31/2023 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
01/31/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
01/12/2023 |
4
| MANCHESTER MANAGEMENT CO LLC (Director by Deputization) has filed a Form 4 on SANUWAVE Health, Inc.
Txns:
| Disposed of options to buy
@ $0.04, valued at
$0 Disposed of 20,000,000 warrants
@ $0 |
|
11/18/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
11/14/2022 |
8-K
| Quarterly results
Docs:
|
"Press Release",
"Eden Prairie, MN, August 15, 2022 - SANUWAVE Health, Inc. a leading provider of next-generation wound care products, reported financial results for their second quarter, ending June 30, 2022, with the SEC on Friday, August 12, 2022. The Company will host a live conference call on Tuesday August 16, 2022, at 12:30 to provide a business update . Quarter Highlights: - Over 50 systems placed to treat wounds o 100% increase from the 25 systems placed Q2 2021 - Over 40,000 wound treatments administered o Up from 31,000 treatments administered Q2 2021 - Successfully completed MDSAP audit - Transitioned company from Suwanee GA to Eden Prairie MN - Became current on SEC filings - Launched Cosmetic and Orthopedics verticals with initial sales in each “Our key ENERGY FIRST products, dermaPACE® and Ul..." |
|
11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/07/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
|
|
|